They're both slow-growing, and you treat them the same way. The only difference is where these cancers start: Mantle cell lymphoma (MCL) is a rare and fast-growing cancer. About 6% of all non ...

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and ...

In a case report published in the World Journal of Oncology, an elderly female patient was diagnosed with mast cell leukemia (MCL), with imaging showing extensive osteoblastic metastatic lesions. MCL ...

There are currently dozens of clinical trials examining new ways to treat mantle cell lymphoma (MCL). People can learn about trial recruitment at ClinicalTrials.gov. Research into mantle cell ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

The ELM-2 trial included 5 independent disease-specific groups (DLBCL, FL, mantle cell lymphoma, marginal zone lymphoma and other subtypes of B-cell non-Hodgkin lymphoma). Among the 128 R/R FL ...

This approval augments Biocon Pharma's complex injectables portfolio and reinforces its footprint in the US pharma market.

DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR T-cell therapy with a 4-1BB co-stimulatory domain, which enhances ...